Olema Pharmaceuticals Q2 EPS $(0.54) Beats $(0.55) Estimate
Portfolio Pulse from Benzinga Newsdesk
Olema Pharmaceuticals (NASDAQ:OLMA) reported a Q2 EPS of $(0.54), beating the analyst consensus estimate of $(0.55) by 1.82%. This represents a 10.2% increase in losses compared to $(0.49) per share from the same period last year.
August 06, 2024 | 8:39 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Olema Pharmaceuticals reported a Q2 EPS of $(0.54), beating the analyst estimate of $(0.55). However, the losses increased by 10.2% compared to the same period last year.
The slight beat on EPS estimates is a positive signal for investors, suggesting better-than-expected performance. However, the increase in losses year-over-year may temper enthusiasm. Overall, the short-term impact is likely positive due to the beat on estimates.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100